Chemotherapy and Surgery for Recurrent Ovarian Cancer

Plain-English translation of NCT06292286 on ClinicalTrials.gov ↗ · Source last updated June 2025 · Translation generated August 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a treatment approach for ovarian cancer that has returned after initial treatment. Patients will receive platinum-based chemotherapy, with or without bevacizumab, followed by surgery to remove remaining cancer. The study wants to see how well this two-step approach works and whether it is safe.

When ovarian cancer comes back after initial treatment, doctors need better ways to control it. This trial is exploring whether giving the medication before surgery helps surgeons remove all the cancer more completely, which could improve how well patients do.

Do you qualify?

You likely qualify if…

you have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
your cancer has come back for the first time after your initial chemotherapy treatment
it has been at least 6 months since your last platinum-based chemotherapy
your doctor believes you cannot have surgery right away and would benefit from chemotherapy first
you are in good enough overall health to receive chemotherapy and surgery (Eastern Cooperative Oncology Group score 0–2)
your blood counts, kidney function, liver function, and nerve function are adequate

You likely don't qualify if…

you have a non-epithelial or borderline ovarian tumor
you have had another cancer (other than skin cancer or certain early-stage breast or uterine cancers) in the last 5 years
you have received more than one previous line of chemotherapy
your cancer is platinum-resistant or came back during/immediately after your last platinum treatment
your cancer has already come back a second time or more

What participation looks like

You will receive platinum-based chemotherapy (possibly with bevacizumab) over several cycles, followed by surgery to remove the cancer. Throughout the study, your doctors will monitor your health with blood tests, imaging, and physical exams to track how well the treatment is working and to watch for any side effects. The study will follow you to see how long you survive and whether the cancer comes back again.

AI-generated summary from trial data · Aug 2, 2026 · Not medical advice

Trial locations(1 site)

Hong Kong

The University of Hong Kong, Hong Kong